STOK Relative Valuation
STOK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, STOK is overvalued; if below, it's undervalued.
Historical Valuation
Stoke Therapeutics Inc (STOK) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -7.95. The fair price of Stoke Therapeutics Inc (STOK) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 31.05 USD , Stoke Therapeutics Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：31.05
Fair
Undervalued
-10.03
PE
1Y
3Y
5Y
Trailing
Forward
-8.29
EV/EBITDA
Stoke Therapeutics Inc. (STOK) has a current EV/EBITDA of -8.29. The 5-year average EV/EBITDA is -5.26. The thresholds are as follows: Strongly Undervalued below -17.72, Undervalued between -17.72 and -11.49, Fairly Valued between 0.97 and -11.49, Overvalued between 0.97 and 7.20, and Strongly Overvalued above 7.20. The current Forward EV/EBITDA of -8.29 falls within the Historic Trend Line -Fairly Valued range.
-7.24
EV/EBIT
Stoke Therapeutics Inc. (STOK) has a current EV/EBIT of -7.24. The 5-year average EV/EBIT is -4.90. The thresholds are as follows: Strongly Undervalued below -16.75, Undervalued between -16.75 and -10.82, Fairly Valued between 1.03 and -10.82, Overvalued between 1.03 and 6.96, and Strongly Overvalued above 6.96. The current Forward EV/EBIT of -7.24 falls within the Historic Trend Line -Fairly Valued range.
99.74
PS
Stoke Therapeutics Inc. (STOK) has a current PS of 99.74. The 5-year average PS is 37.84. The thresholds are as follows: Strongly Undervalued below -15.46, Undervalued between -15.46 and 11.19, Fairly Valued between 64.49 and 11.19, Overvalued between 64.49 and 91.14, and Strongly Overvalued above 91.14. The current Forward PS of 99.74 falls within the Strongly Overvalued range.
-11.67
P/OCF
Stoke Therapeutics Inc. (STOK) has a current P/OCF of -11.67. The 5-year average P/OCF is -11.46. The thresholds are as follows: Strongly Undervalued below -35.13, Undervalued between -35.13 and -23.30, Fairly Valued between 0.37 and -23.30, Overvalued between 0.37 and 12.21, and Strongly Overvalued above 12.21. The current Forward P/OCF of -11.67 falls within the Historic Trend Line -Fairly Valued range.
-10.49
P/FCF
Stoke Therapeutics Inc. (STOK) has a current P/FCF of -10.49. The 5-year average P/FCF is -46.48. The thresholds are as follows: Strongly Undervalued below -379.61, Undervalued between -379.61 and -213.04, Fairly Valued between 120.09 and -213.04, Overvalued between 120.09 and 286.65, and Strongly Overvalued above 286.65. The current Forward P/FCF of -10.49 falls within the Historic Trend Line -Fairly Valued range.
Stoke Therapeutics Inc (STOK) has a current Price-to-Book (P/B) ratio of 5.55. Compared to its 3-year average P/B ratio of 2.48 , the current P/B ratio is approximately 124.44% higher. Relative to its 5-year average P/B ratio of 3.12, the current P/B ratio is about 77.94% higher. Stoke Therapeutics Inc (STOK) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -15.56%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -11.33% , the current FCF yield is about -100.00% lower.
5.55
P/B
Median3y
2.48
Median5y
3.12
2.96
FCF Yield
Median3y
-15.56
Median5y
-11.33
Competitors Valuation Multiple
The average P/S ratio for STOK's competitors is 6.32, providing a benchmark for relative valuation. Stoke Therapeutics Inc Corp (STOK) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 117.25%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of STOK increased by 181.50% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 4.89M to 10.63M.
The secondary factor is the P/E Change, contributed 97.46%to the performance.
Overall, the performance of STOK in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Stoke Therapeutics Inc (STOK) currently overvalued or undervalued?
What is Stoke Therapeutics Inc (STOK) fair value?
How does STOK's valuation metrics compare to the industry average?
What is the current P/B ratio for Stoke Therapeutics Inc (STOK) as of Dec 05 2025?
What is the current FCF Yield for Stoke Therapeutics Inc (STOK) as of Dec 05 2025?
What is the current Forward P/E ratio for Stoke Therapeutics Inc (STOK) as of Dec 05 2025?